Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 1, 2015, Pages

  Thinkhamrop, Jadsada ^a   Hofmeyr, G Justus ^b   Adetoro, Olalekan ^c   Lumbiganon, Pisake ^a   Ota, Erika ^d  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c OLABISI ONABANJO UNIVERSITY   (Nigeria)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; CEFETAMET PIVOXIL; CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; ERYTHROMYCIN STEARATE; METRONIDAZOLE; PLACEBO;

ADVERSE OUTCOME; ANTIBIOTIC PROPHYLAXIS; BIRTH WEIGHT; CHORIOAMNIONITIS; CONGENITAL MALFORMATION; ENDOMETRITIS; GESTATIONAL AGE; GONORRHEA; HIGH RISK PREGNANCY; HUMAN; LOW BIRTH WEIGHT; MEDICATION COMPLIANCE; MORBIDITY; NEWBORN SEPSIS; PATIENT COMPLIANCE; PERINATAL MORTALITY; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; SEPSIS; SINGLE DRUG DOSE; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; COMPLICATION; DRUG EFFECTS; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; FETUS WEIGHT; META ANALYSIS; PREGNANCY; PREMATURE BIRTH; VAGINITIS; CONGENITAL DISORDER; FEVER; FOLLOW UP; MATERNAL MORBIDITY; PREGNANT WOMAN;

ANTIBIOTIC PROPHYLAXIS; ENDOMETRITIS; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; FETAL WEIGHT; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; VAGINOSIS, BACTERIAL;

EID: 84948163197     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002250.pub2     Document Type: Review

References (66)

1. Gichangi PB, Ndinya-Achola JO, Ombete J, Nagelkerke NJ, Temmerman M. Antimicrobial prophylaxis in pregnancy: a randomized placebo-controlled trial with cefetamet-pivoxil in pregnant women with a poor obstetric history. American Journal of Obstetrics and Gynecology 1997;177:680-4.
2. Hauth JC, Goldenberg LR, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. New England Journal of Medicine 1995;333:1732-6.
3. McGregor JA, French JI, Richter R, Vuchetich M, Bachus V, Franco-Buff A, et al.Prospective, double-blinded, randomized, placebo-controlled trial of short-course erythromycin (E) base in women at high risk for preterm birth. Proceedings of the Society for Gynecologic Investigation; 1988. 1988.
4. McGregor JA, French JI, Richter R, Vuchetich M, Bachus V, Seo K, et al.Cervicovaginal microflora and pregnancy outcome: results of a double-blind, placebo-controlled trial of erythromycin treatment. American Journal of Obstetrics and Gynecology 1990;163:1580-91.
5. Paul VK, Singh M, Buckshee K. Erythromycin treatment of pregnant women to reduce the incidence of low birth weight and preterm deliveries. International Journal of Gynecology & Obstetrics 1998;62:87-8.
6. Sen A, Mahalanabis D, Mukhopadhyay S, Chakrabarty K, Singh AK, Bisai S, et al.Routine use of antimicrobials by pregnant Indian women does not improve birth outcome: a randomized controlled trial. Journal of Health, Population & Nutrition 2005;23(3):236-44.
7. Temmerman M, Njagi E, Nagelkerke N, Ndinya-Achola J, Plummer FA, Meheus A. Mass antimicrobial treatment in pregnancy, a randomized, placebo-controlled trial in a population with high rates of sexually transmitted diseases. Journal of Reproductive Medicine 1995;40:176-80.
8. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. British Journal of Obstetrics and Gynaecology 1999;106:652-7.
9. Anderson B, Zhao Y, Andrews WW, Dudley DJ, Sibai B, Iams JD, et al.Effect of antibiotic exposure on Nugent score among pregnant women with and without bacterial vaginosis. Obstetrics & Gynecology 2011;117(4):844-9.
10. Andrews WW, Sibai BM, Thom EA, Dudley D, Ernest JM, McNellis D, et al.Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstetrics & Gynecology 2003;101(5 Pt 1):847-55.
11. Hendler I, Andrews WW, Carey CJ, Klebanoff MA, Noble WD, Sibai BM, et al.The relationship between resolution of asymptomatic bacterial vaginosis and spontaneous preterm birth in fetal fibronectin-positive women. American Journal of Obstetrics and Gynecology 2007;197(5):488.e1-488.e5.
12. Lin M, for the NICHD MFMU Network. Impact of quantitative fetal fibronectin (FFN) change of efficacy of antibiotic vs. placebo treatment of asymptomatic FFN positive women to prevent subsequent preterm birth [abstract]. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S56.
13. Ramsey P. Relationship of midtrimester fetal fibronectin (FFN) concentration to antibiotic efficacy for the prevention of spontaneous preterm birth in asymptomatic FFN positive women [abstract]. American Journal of Obstetrics and Gynecology 2004;191(6 Suppl 1):S11.
14. Andrews W, Goldenberg R, Hauth J, Cliver S. Interconceptional antibiotics to prevent spontaneous preterm birth (SPTB): a randomized trial [abstract]. American Journal of Obstetrics and Gynecology 2003;189(6 Suppl 1):s57.
15. Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Copper R, Conner M. Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. American Journal of Obstetrics and Gynecology 2006;194(3):617-23.
16. Tita A, Cliver S, Goepfert A, Goldenberg R, Conner M, Andrews W. Impact of interconceptional antibiotics on the "endometrial flora". American Journal of Obstetrics and Gynecology 2006;195(6 Suppl 1):S17.
17. Tita A, Cliver S, Goepfert A, Goldenberg R, Conner M, Andrews W. Interconceptional antibiotics and preterm delivery: subgroup analyses. American Journal of Obstetrics and Gynecology 2006;195(6 Suppl 1):S76.
18. Tita AT, Cliver SP, Goepfert AR, Conner M, Goldenberg RL, Hauth JC, et al.Impact of interconception antibiotics on the endometrial microbial flora. American Journal of Obstetrics and Gynecology 2007;196(3):226.e1-226.e6.
19. Tita AT, Cliver SP, Goepfert AR, Conner M, Goldenberg RL, Hauth JC, et al.Clinical trial of interconceptional antibiotics to prevent preterm birth: subgroup analyses and possible adverse antibiotic-microbial interaction. American Journal of Obstetrics and Gynecology 2007;197(4):367.e1-6.
20. Audebert AJM. Use of polygynax in pregnant women for preventing cervico-vaginal infections. Revue Francaise de Gynecologie et d Obstetrique 1989;84:287-90.
21. Aboud S, Msamanga G, Read JS, Wang L, Mfalila C, Sharma U, et al.Effect of prenatal and perinatal antibiotics on maternal health in Malawi, Tanzania, and Zambia. International Journal of Gynecology & Obstetrics 2009;107(3):202-7.
22. Goldenberg R, Andrews W, Taha T, Fawzi W, Brown E. HIVNET 024: fetal fibronectin (FFN), preterm birth (PTB) and mother to child transmission of HIV (MTCT) in African women with HIV [abstract]. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S52.
23. Goldenberg R, Mudenda V, Brown E, Taha T, Kaaya E. HIVNET 024: neutrophilic and mononuclear placental infiltration, antibiotics and outcome in an African population [abstract]. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S188.
24. Goldenberg R, Taha T, Hoffman I, Fawzi W, Mwatha A. HPTN 024: antibiotics do not prevent preterm birth (PTB) in an HIV-infected African population [abstract]. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S3.
25. Goldenberg RL, Mudenda V, Read JS, Brown ER, Sinkala M, Kamiza S, et al.HPTN 024 study: histologic chorioamnionitis, antibiotics and adverse infant outcomes in a predominantly HIV-1-infected African population. American Journal of Obstetrics & Gynecology 2006;195(4):1065-74.
26. Goldenberg RL, Mwatha A, Read JS, Adeniyi-Jones S, Sinkala M, Msmanga G, et al.The HPTN 024 study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. American Journal of Obstetrics and Gynecology 2006;194(3):650-61.
27. Kafulafula G, Mwatha A, Chen YQ, Aboud S, Martinson F, Hoffman I, et al.Intrapartum antibiotic exposure and early neonatal, morbidity, and mortality in Africa. Pediatrics 2009;124(1):e137-44.
28. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. South African Medical Journal 2010;100(1):58-64.
29. Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, et al.A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006;20(9):1313-21.
30. Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, Moulton LH, et al.Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. American Journal of Obstetrics & Gynecology 2001;185:1209-17.
31. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, Wawer MJ, Serwadda D, Sewankambo N, et al.Treatment of trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. American Journal of Obstetrics and Gynecology 2003;189:1398-400.
32. Larsson PG, Fahraeus L, Carlsson B, Jakobsson T, Forsum U, the premature study group of the southeast health care region of Sweden. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG: an international journal of obstetrics and gynaecology 2006;113(6):629-37.
33. Ashorn P. Gestational sulfadoxine-pyrimethamine and azithromycin treatment to prevent preterm birth (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006) 2006.
34. Luntamo M, Kulmala T, Cheung YB, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. Tropical Medicine & International Health 2013;18(4):386-97.
35. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of repeated treatment of pregnant women with sulfadoxine- pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. American Journal of Tropical Medicine and Hygiene 2010;83(6):1212-20.
36. Peter MT, Brown CEL, Buam A, Risser R. Randomized, double-blind, placebo-controlled trial of amoxycillin/clavulanic acid to prevent preterm delivery in twin gestation. Infectious Diseases in Obstetrics and Gynecology 1995;3:158-63.
37. Kurtzman J, Chandiramani M, Briley A, Poston L, Shennan A. Minimal quantitative levels of fetal fibronectin (1-49 NG/ML) at 24-27 weeks are associated with an increased risk of recurrent preterm delivery in asymptomatic patients with prior preterm birth. American Journal of Obstetrics and Gynecology 2008;199(6 Suppl 1):S47.
38. Kurtzman J, Chandiramani M, Briley A, Poston L, Shennan A. Quantitative fetal fibronectin screening at 24 weeks substantially discriminates the risk of recurrent preterm delivery in asymptomatic patients with prior preterm birth. American Journal of Obstetrics and Gynecology 2008;199(6 Suppl 1):S10.
39. Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, et al.A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET study. BJOG: an international journal of obstetrics and gynaecology 2006;113(1):65-74.
40. Thompson C. Taken before their time. Nursing Times 2002;98(3):29.
41. Gupta S, Tripathi R, Singh N, Bhalla P, Ramji S, Mala YM. Pregnancy outcome in asymptomatic women with abnormal vaginal flora without any treatment and after treatment with vaginal clindamycin and clotrimazole: a randomised controlled trial. South African Journal of Obstetrics and Gynaecology 2013;19(2):35-8.
42. Tripathi R, Gupta S, Bhalla P, Mala YM, Tyagi S, Ramji S. Maternal and fetal outcome in patients with abnormal vaginal flora after treatment with vaginal clindamycin in early pregnancy. BJOG: an international journal of obstetrics and gynaecology 2008;115(s1):161.
43. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, et al.The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. PLoS Medicine 2009;6(12):e1000191.
44. Hoffman M. Clindamycin to reduce preterm birth in a low resource setting. ClinicalTrials.gov (accessed 21 May 2013) 2013.
45. Rathjen P. Intermittent preventive treatment with azithromycin-containing regimens in pregnant women in Papua New Guinea (IPTp in PNG). ClinicalTrials.gov (http://clinicaltrials.gov) [accessed April 2013) 2010.
46. Braun P, Lee Y, Klein JO, Marcy M, Klein TA, Charles D. Birth weight and genital mycoplasma in pregnancy. New England Journal of Medicine 1971;284:167-74.
47. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDV, et al.Williams Obstetrics. 20th Edition. Norwalk, CT: Appleton & Lange, 1997.
48. Eschenbach DA, Nugent RP, Rao VA, Cotch MF, Gibbs RS, Lipscomb KA, et al.A randomized placebo controlled trial of erythromycin for the treatment of ureaplasma urealyticum in preventing premature delivery. American Journal of Obstetrics and Gynecology 1991;164:734-42.
49. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.6. The Cochrane Collaboration, 2008.
50. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK. Independent associations of bacterial vaginosis and chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 1986;256:1899-905.
51. Hardy PH, Nell EE, Spence MR, Hardy JB, Graham DA, Rosenbaum RC. Prevalence of six sexually transmitted disease agents among pregnant innercity adolescents and pregnancy outcome. Lancet 1984;8:333-7.
52. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al.Association between bacterial vaginosis and preterm delivery of low-birth weight infant. New England Journal of Medicine 1995;333:1737-42.
54. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al.Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008;372(9646):1319-27.
55. Lettieri L, Vintzileos AM, Rodis JF, Albini SM, Saladia CM. Does idiopathic preterm labor resulting in preterm birth exist?. American Journal of Obstetrics and Gynecology 1993;168:1480-5.
56. Lin M, for the NICHD MFMU Network. Impact of quantitative fetal fibronectin (FFN) change of efficacy of antibiotic vs. placebo treatment of asymptomatic FFN positive women to prevent subsequent preterm birth [abstract]. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S56.
57. McCormack WM, Rosner B, Lee YH, Munoz A, Kass CD. Effect on birth weight of erythromycin in treatment of pregnant women. Obstetrics & Gynecology 1987;69:202-7.
58. Morales JW, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo controlled double blind study. Obstetrics & Gynecology 1994;171:345-9.
59. Newton ER, Dinsmoor MJ, Gibbs RS. A randomised blinded placebo controlled trial of antibiotics in idiopathic preterm labour. Obstetrics & Gynecology 1989;74:562-6.
60. Oleszczuk JJ, Keith LG. Vaginal infection: prophylaxis and perinatal outcome-a review of the literature. International Journal of Fertility 2000;45(6):358-67.
61. Regan JA, Chao S, James SL. Premature rupture of membranes, preterm delivery, and group B streptococcal colonization of mothers. American Journal of Obstetrics and Gynecology 1981;141:184-6.
62. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
63. Romero R, Mazor M. Infection and preterm labor. Clinical Obstetrics and Gynecology 1988;31:553-83.
64. Romero R, Sibai B, Caritis S, Paul R, Depp R, Rosen M, et al.Antibiotic treatment of preterm labour with intact membranes: a multicenter randomised double blinded controlled trial. American Journal of Obstetrics and Gynecology 1993;169:764-74.
65. Schunemann HJ. GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice [GRADE: Von der Evidenz zur Empfehlung. Beschreibung des Systems und Losungsbeitrag zur Ubertragbarkeit von Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2009;103(6):391-400.
66. Thinkhamrop J, Hofmeyr GJ, Adetoro O, Lumbiganon P. Prophylactic antibiotic administration during second and third trimester in pregnancy for preventing infectious morbidity and mortality. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002250]